326 related articles for article (PubMed ID: 22907887)
1. Lessons learned from next-generation sequencing in head and neck cancer.
Loyo M; Li RJ; Bettegowda C; Pickering CR; Frederick MJ; Myers JN; Agrawal N
Head Neck; 2013 Mar; 35(3):454-63. PubMed ID: 22907887
[TBL] [Abstract][Full Text] [Related]
2. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
3. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
4. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
6. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
[TBL] [Abstract][Full Text] [Related]
7. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
[TBL] [Abstract][Full Text] [Related]
8. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
10. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
[TBL] [Abstract][Full Text] [Related]
11. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
[TBL] [Abstract][Full Text] [Related]
12. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Agrawal N; Frederick MJ; Pickering CR; Bettegowda C; Chang K; Li RJ; Fakhry C; Xie TX; Zhang J; Wang J; Zhang N; El-Naggar AK; Jasser SA; Weinstein JN; Treviño L; Drummond JA; Muzny DM; Wu Y; Wood LD; Hruban RH; Westra WH; Koch WM; Califano JA; Gibbs RA; Sidransky D; Vogelstein B; Velculescu VE; Papadopoulos N; Wheeler DA; Kinzler KW; Myers JN
Science; 2011 Aug; 333(6046):1154-7. PubMed ID: 21798897
[TBL] [Abstract][Full Text] [Related]
13. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
[TBL] [Abstract][Full Text] [Related]
14. Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.
Wu ES; Park JY; Zeitouni JA; Gomez CR; Reis IM; Zhao W; Kwon D; Lee E; Nelson OL; Lin HY; Franzmann EJ; Savell J; McCaffrey TV; Goodwin WJ; Hu JJ
Head Neck; 2016 Aug; 38(8):1234-41. PubMed ID: 27028310
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
16. Genomic analysis of metastatic cutaneous squamous cell carcinoma.
Li YY; Hanna GJ; Laga AC; Haddad RI; Lorch JH; Hammerman PS
Clin Cancer Res; 2015 Mar; 21(6):1447-56. PubMed ID: 25589618
[TBL] [Abstract][Full Text] [Related]
17. Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.
Nichols AC; Yoo J; Palma DA; Fung K; Franklin JH; Koropatnick J; Mymryk JS; Batada NN; Barrett JW
Arch Otolaryngol Head Neck Surg; 2012 Aug; 138(8):732-9. PubMed ID: 22911296
[TBL] [Abstract][Full Text] [Related]
18. The mutational landscape of head and neck squamous cell carcinoma.
Stransky N; Egloff AM; Tward AD; Kostic AD; Cibulskis K; Sivachenko A; Kryukov GV; Lawrence MS; Sougnez C; McKenna A; Shefler E; Ramos AH; Stojanov P; Carter SL; Voet D; Cortés ML; Auclair D; Berger MF; Saksena G; Guiducci C; Onofrio RC; Parkin M; Romkes M; Weissfeld JL; Seethala RR; Wang L; Rangel-Escareño C; Fernandez-Lopez JC; Hidalgo-Miranda A; Melendez-Zajgla J; Winckler W; Ardlie K; Gabriel SB; Meyerson M; Lander ES; Getz G; Golub TR; Garraway LA; Grandis JR
Science; 2011 Aug; 333(6046):1157-60. PubMed ID: 21798893
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive mutation analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 genes is suggestive of a non- neoplastic nature of phenytoin induced gingival overgrowth.
Swamikannu B; Kumar KS; Jayesh RS; Rajendran S; Muthupalani RS; Ramanathan A
Asian Pac J Cancer Prev; 2013; 14(5):2743-6. PubMed ID: 23803025
[TBL] [Abstract][Full Text] [Related]
20. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]